LONDON (Alliance News) - GlaxoSmithKline PLC on Thursday said lupus patients treated with its Benlysta drug over five years experienced low rates of organ damage progression, regardless of their baseline level of damage.
The pharmaceutical giant said the results came from two pooled studies of Benlysta, which is its treatment for moderate-to-severe systemic lupus erythematosus and received a regulatory licence for Europe in 2011. Patients with SLE are at risk of irreversible organ damage which will accrue over time and is associated with increased risk of death.
Shares in GlaxoSmithKline were down 2.0% at 1,368.50 pence on Thursday afternoon.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.